Halozyme Therapeutics reported $165.16M in Net Income for its fiscal quarter ending in June of 2025.




Net Income Change Date
Acadia Pharmaceuticals USD 26.67M 7.68M Jun/2025
Agios Pharmaceuticals USD -112020000 22.73M Jun/2025
Alnylam Pharmaceuticals USD -66277000 8.8M Jun/2025
Amarin USD -15697000 32.92M Mar/2025
Amgen USD 1.43B 298M Jun/2025
Baxter International USD 91M 35M Jun/2025
Cytokinetics USD -134370000 27.01M Jun/2025
DBV Technologies USD -41875000 14.8M Jun/2025
Eli Lilly USD 5.66B 2.9B Jun/2025
Halozyme Therapeutics USD 165.16M 47.06M Jun/2025
Ionis Pharmaceuticals USD 123.55M 270.49M Jun/2025
MannKind USD 668K 12.49M Jun/2025
Pfizer USD 2.91B 58M Jun/2025
United Therapeutics USD 309.5M 12.7M Jun/2025